KEY POINTS
- This retrospective single-center study from Zhongshan Hospital, Fudan University, Shanghai, analyzed 76 patients with unresectable hepatocellular carcinoma (HCC) and hepatic vein tumor thrombus (HVTT) treated between January 2020 and December 2023. 36 patients received permanent iodine-125 seed-strand implantation plus TACE, lenvatinib, and camrelizumab, while 40 received TACE, lenvatinib, and camrelizumab without brachytherapy. Eligible patients had Vv1 or Vv2 HVTT, Child-Pugh A–B liver function, ECOG performance status 0–2, and no previous locoregional or systemic HCC treatment. Treatment allocation was determined by patient choice rather than randomization.
- Endovascular brachytherapy delivered continuous low-dose-rate irradiation directly along the tumor thrombus. A mean of 25.6 iodine-125 seeds (range 20–30) were loaded into a flexible strand and permanently implanted within the affected hepatic vein under image guidance. The calculated intended dose was 64.0 ± 0.3 Gy at 10 mm from the strand axis over 240 days, rather than a uniform dose throughout the tumor thrombus. TACE was performed on the same day, while both groups received weight-adjusted lenvatinib 8–12 mg daily and camrelizumab 200 mg every two weeks. Subsequent TACE was permitted for residual or recurrent intrahepatic disease.
- The primary endpoint of overall survival significantly favored the brachytherapy-containing regimen. Median OS was 22.1 months (95% CI 17.5–26.7) with iodine-125 implantation versus 14.0 months (95% CI 10.7–17.3) without it, an absolute difference of 8.1 months (log-rank p<0.001). In multivariable Cox analysis including treatment regimen and Child-Pugh class, the brachytherapy-containing approach remained associated with lower mortality (HR 0.280, 95% CI 0.154–0.509; p<0.001). These adjusted results remain observational associations and cannot eliminate selection bias.
- Progression-free survival was also significantly longer with the addition of iodine-125 brachytherapy. Median PFS increased from 8.0 months (95% CI 6.7–9.2) in the control group to 17.6 months (95% CI 17.0–18.2) in the brachytherapy group (p<0.001). Estimated 12-month overall survival was 83.3% versus 60.0%, and 24-month survival was 44.4% versus 15.0%, respectively. However, mean follow-up differed between groups (18.8 ± 6.9 vs 12.6 ± 5.2 months), and the late survival estimates were based on progressively smaller numbers at risk.
- Tumor-thrombus response was substantially higher with endovascular brachytherapy. The HVTT objective response rate, defined by complete disappearance or at least 50% reduction in thrombus cross-sectional area, was 72.2% versus 15.0% (p<0.001). The corresponding disease control rate was 88.9% versus 35.0% (p<0.001). Complete HVTT responses occurred in 3/36 patients receiving the seed strand and none of the 40 controls, while progressive thrombus disease occurred in 4/36 versus 26/40. These findings suggest improved local thrombus control, but do not independently establish a survival effect.
- Response differences extended beyond the irradiated hepatic vein. For intrahepatic HCC lesions, the objective response rate was 50.0% with brachytherapy versus 17.5% without (p=0.003), while the disease control rate was 63.9% versus 35.0% (p=0.012). Lung metastases were subsequently documented in 2/36 patients (5.6%) versus 16/40 (40.0%; p<0.001). Although these differences are clinically notable, the groups were not randomized and no propensity-matched analysis was performed, so a systemic protective effect from the local irradiation cannot be inferred.
- No serious complications directly attributed to iodine-125 implantation were reported. Technical implantation was successful in all 36 patients, with no seed-strand displacement on postprocedural imaging and no documented hepatic vein stenosis, occlusion, radiation-induced liver disease, or treatment-related death. Grade 3 systemic-treatment toxicities, including diarrhea and hypertension, occurred, but no grade 4 adverse events were reported. Interpretation is limited by the small cohort, patient-selected treatment, predominantly Child-Pugh A liver function, exclusion of Vv3 thrombus extending into the inferior vena cava, and lack of independent patient-specific radiation dosimetry or late toxicity validation.
CLINICAL TAKEAWAY
Adding permanent iodine-125 endovascular brachytherapy to TACE, lenvatinib, and camrelizumab was associated with substantially longer survival and improved thrombus control in patients with unresectable HCC and Vv1–Vv2 hepatic vein tumor thrombus. These findings suggest that local treatment of hepatic venous invasion may be clinically valuable, but the small nonrandomized cohort and patient-selected treatment allocation prevent conclusions about the independent benefit of brachytherapy. Prospective randomized evaluation is needed before adopting this combined regimen routinely.